Acalabrutinb + BR and sotorasib + panitumumab
Jan 30, 2025•9 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
FDA approves two new treatment regimens:
1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT
2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)
For the best experience, listen in Metacast app for iOS or Android